trial

Pharmacogenetics of Cannabinoid Response

NCTId NCT00678730
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Early Phase 1 · Completed
Enrollment 72 (actual)
Sponsored by Yale University
Primary completion 2014-09-11
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Early Phase 1
Status
Completed
Enrollment
72 (actual)
Study type
Interventional
Allocation
Randomized
Model
Crossover
Masking
Quadruple
Start
2007-08-23
Primary completion
2014-09-11
Eligibility
ALL · 18 Years · 55 Years

Interventions & indications

Drugs
delta 9 tetrahydrocannabinol

Sponsors

Yale UniversityLead Sponsor
National Institute on Drug Abuse (NIDA)Collaborator

Investigators

1
Deepak C D'Souza, M.D.Principal Investigator

Sites

1 total
West Haven, United States

Facts & assertions

4 sourced
Enrollment
72
Phase
EARLY_PHASE1
Primary Completion Date
2014-09-11
Status
COMPLETED
relationships
The graph out of here
drug
delta 9 tetrahydrocannabinol
drug
lead_sponsor
Yale University
company
collaborator
National Institute on Drug Abuse (NIDA)
company
indication
COMT Gene Polymorphism
indication
Schizophrenia
indication
investigator
Deepak C D'Souza, M.D.
person